[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-001", "question": "A 45-year-old man with a history of alcoholic cirrhosis presents to the ICU with massive upper gastrointestinal bleeding. Despite endoscopic intervention and octreotide infusion, bleeding persists, and he develops hemodynamic instability. Transjugular intrahepatic portosystemic shunt (TIPS) is considered, but imaging reveals a rare anatomical variant. What is the most appropriate next step in management?", "options": ["Proceed with TIPS using a covered stent to mitigate risks", "Initiate balloon tamponade with a Sengstaken-Blakemore tube", "Administer terlipressin as an alternative vasoconstrictor", "Perform urgent surgical portocaval shunt", "Refer for angiographic embolization of the coronary vein"], "answer": "E", "answer_index": 4, "explanation": "In persistent variceal bleeding with anatomical variants precluding TIPS, angiographic embolization targets specific bleeding vessels like the coronary vein, offering a less invasive option. TIPS is contraindicated due to the variant, while surgical shunts carry high mortality in unstable patients. Terlipressin and balloon tamponade are temporizing but not definitive here.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified) leading to N (No answer defensible). Verdict: Not uniquely determinable. The stem states 'imaging reveals a rare anatomical variant' but provides no specifics about what variant exists or why it precludes TIPS. This critical omission makes it impossible to determine the appropriate next step. Key stem clues: 45-year-old with alcoholic cirrhosis, massive UGI bleeding refractory to endoscopy and octreotide, hemodynamically unstable, unspecified anatomical variant. The keyed answer (E: angiographic embolization of coronary vein) assumes the variant specifically affects portal-hepatic venous anatomy while leaving gastric varices accessible to embolization—an unstated assumption. However, balloon tamponade (B) is the standard temporizing measure for refractory variceal bleeding regardless of anatomy, and would be appropriate in an unstable patient while definitive options are explored. The rationale dismisses tamponade as 'temporizing but not definitive,' yet embolization is also not universally definitive for variceal bleeding. Medical accuracy issues: Coronary vein embolization is a specialized technique not widely considered standard first-line therapy; balloon tamponade is more universally accepted for refractory bleeding. The item conflates anatomical contraindication to TIPS with indication for a specific alternative without justification. Minimal fix: Specify the anatomical variant (e.g., 'portal vein thrombosis with patent left gastric/coronary vein') to justify embolization as the logical choice.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to N (No answer defensible). Verdict: Not uniquely determinable. The stem states 'imaging reveals a rare anatomical variant' but provides no specifics about what variant exists or why it precludes TIPS. This critical omission makes it impossible to determine the appropriate next step. Key stem clues: 45-year-old with alcoholic cirrhosis, massive UGI bleeding refractory to endoscopy and octreotide, hemodynamically unstable, unspecified anatomical variant. The keyed answer (E: angiographic embolization of coronary vein) assumes the variant specifically affects portal-hepatic venous anatomy while leaving gastric varices accessible to embolization—an unstated assumption. However, balloon tamponade (B) is the standard temporizing measure for refractory variceal bleeding regardless of anatomy, and would be appropriate in an unstable patient while definitive options are explored. The rationale dismisses tamponade as 'temporizing but not definitive,' yet embolization is also not universally definitive for variceal bleeding. Medical accuracy issues: Coronary vein embolization is a specialized technique not widely considered standard first-line therapy; balloon tamponade is more universally accepted for refractory bleeding. The item conflates anatomical contraindication to TIPS with indication for a specific alternative without justification. Minimal fix: Specify the anatomical variant (e.g., 'portal vein thrombosis with patent left gastric/coronary vein') to justify embolization as the logical choice.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-002", "question": "A 62-year-old woman with metastatic breast cancer on paclitaxel develops acute dyspnea and hypoxemia. CT angiography shows no pulmonary embolism, but echocardiography reveals right ventricular strain. Bone marrow biopsy confirms tumor infiltration. What is the most likely diagnosis?", "options": ["Paclitaxel-induced pneumonitis", "Tumor microembolism syndrome", "Lymphangitic carcinomatosis", "Chemotherapy-associated pulmonary veno-occlusive disease", "Metastatic tumor thrombus in pulmonary arteries"], "answer": "B", "answer_index": 1, "explanation": "Tumor microembolism syndrome occurs when tumor cells embolize to pulmonary vasculature, causing right heart strain without macroscopic emboli, fitting this presentation in metastatic cancer. Lymphangitic carcinomatosis typically shows interstitial patterns on imaging, while paclitaxel pneumonitis is inflammatory. Veno-occlusive disease is more associated with stem cell transplant regimens.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes acute dyspnea/hypoxemia, negative CT angiography for PE, RV strain on echo, and bone marrow tumor infiltration in metastatic breast cancer on paclitaxel. The question asks for the \\\"most likely diagnosis.\\\" Key issue: Both B (tumor microembolism) and E (metastatic tumor thrombus in pulmonary arteries) describe tumor emboli to pulmonary vasculature causing RV strain without visible PE on CT angiography. The distinction is semantic rather than clinically meaningful—tumor microemboli ARE tumor thrombi at microscopic scale. The rationale states tumor microembolism causes strain \\\"without macroscopic emboli,\\\" but option E could represent the same pathophysiology. CT angiography has detection limits; microscopic tumor emboli would not be visible on either modality, making both options defensible. Option C (lymphangitic carcinomatosis) is also plausible given metastatic breast cancer and dyspnea, though typically shows interstitial patterns. The bone marrow finding doesn't specifically discriminate between vascular tumor emboli versus lymphatic spread. Medical accuracy: The concept is sound but the distinction between B and E is unclear. Minimal fix: Specify imaging findings that exclude macroscopic pulmonary artery tumor thrombus explicitly, or remove option E, or clarify that lymphangitic spread was ruled out by specific CT findings.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes acute dyspnea/hypoxemia, negative CT angiography for PE, RV strain on echo, and bone marrow tumor infiltration in metastatic breast cancer on paclitaxel. The question asks for the \"most likely diagnosis.\" Key issue: Both B (tumor microembolism) and E (metastatic tumor thrombus in pulmonary arteries) describe tumor emboli to pulmonary vasculature causing RV strain without visible PE on CT angiography. The distinction is semantic rather than clinically meaningful—tumor microemboli ARE tumor thrombi at microscopic scale. The rationale states tumor microembolism causes strain \"without macroscopic emboli,\" but option E could represent the same pathophysiology. CT angiography has detection limits; microscopic tumor emboli would not be visible on either modality, making both options defensible. Option C (lymphangitic carcinomatosis) is also plausible given metastatic breast cancer and dyspnea, though typically shows interstitial patterns. The bone marrow finding doesn't specifically discriminate between vascular tumor emboli versus lymphatic spread. Medical accuracy: The concept is sound but the distinction between B and E is unclear. Minimal fix: Specify imaging findings that exclude macroscopic pulmonary artery tumor thrombus explicitly, or remove option E, or clarify that lymphangitic spread was ruled out by specific CT findings.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-003", "question": "A 28-year-old man presents to the emergency department with severe headache, vomiting, and photophobia after a recent hiking trip. CSF analysis shows lymphocytic pleocytosis, elevated protein, and normal glucose. PCR for common viruses is negative, but serology reveals antibodies to a rare pathogen. What is the most appropriate initial management?", "options": ["Intravenous acyclovir for presumed herpes encephalitis", "Empiric antibiotics for bacterial meningitis", "Supportive care with close monitoring", "Corticosteroids to reduce inflammation", "Antifungal therapy targeting endemic mycoses"], "answer": "C", "answer_index": 2, "explanation": "This presentation suggests lymphocytic meningitis from a rare arbovirus like Jamestown Canyon virus, where supportive care is the mainstay as no specific antiviral exists. Acyclovir is for herpes, unnecessary here with negative PCR. Antibiotics are for bacterial etiologies, ruled out by CSF profile.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes aseptic meningitis after hiking with lymphocytic pleocytosis, elevated protein, normal glucose, negative viral PCR, but positive serology for an unspecified \\\"rare pathogen.\\\" Key discriminating findings: recent hiking, aseptic CSF profile, negative common viral PCR, positive serology for rare pathogen. The vignette is underspecified regarding which rare pathogen and critically lacks temporal information about the serology (acute vs. convalescent titers, IgM vs. IgG). Without knowing the specific pathogen identified by serology, multiple management approaches remain defensible. If the rare pathogen is an endemic fungus (e.g., Coccidioides after hiking in endemic areas), antifungal therapy (E) would be appropriate initial management, not just supportive care. The explanation assumes arbovirus, but arboviruses typically show positive PCR or require paired serologies for diagnosis—single serology is insufficient. The CSF profile with normal glucose also fits fungal meningitis. Both C (supportive care) and E (antifungal) are defensible depending on the unspecified pathogen and clinical context. Medical accuracy issue: assuming supportive care is appropriate without ruling out treatable causes when serology suggests a specific pathogen. Minimal fix: specify the pathogen (e.g., \\\"serology reveals IgM antibodies to Jamestown Canyon virus\\\") or state \\\"serology pending\\\" to justify empiric supportive care.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes aseptic meningitis after hiking with lymphocytic pleocytosis, elevated protein, normal glucose, negative viral PCR, but positive serology for an unspecified \"rare pathogen.\" Key discriminating findings: recent hiking, aseptic CSF profile, negative common viral PCR, positive serology for rare pathogen. The vignette is underspecified regarding which rare pathogen and critically lacks temporal information about the serology (acute vs. convalescent titers, IgM vs. IgG). Without knowing the specific pathogen identified by serology, multiple management approaches remain defensible. If the rare pathogen is an endemic fungus (e.g., Coccidioides after hiking in endemic areas), antifungal therapy (E) would be appropriate initial management, not just supportive care. The explanation assumes arbovirus, but arboviruses typically show positive PCR or require paired serologies for diagnosis—single serology is insufficient. The CSF profile with normal glucose also fits fungal meningitis. Both C (supportive care) and E (antifungal) are defensible depending on the unspecified pathogen and clinical context. Medical accuracy issue: assuming supportive care is appropriate without ruling out treatable causes when serology suggests a specific pathogen. Minimal fix: specify the pathogen (e.g., \"serology reveals IgM antibodies to Jamestown Canyon virus\") or state \"serology pending\" to justify empiric supportive care.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-004", "question": "A 7-year-old boy with autism spectrum disorder presents with recurrent episodes of staring spells and facial twitching. EEG shows multifocal epileptiform discharges, and MRI reveals subtle cortical dysplasia. Genetic testing identifies a de novo mutation. What is the most effective first-line therapy?", "options": ["Valproic acid for broad-spectrum coverage", "Levetiracetam to minimize behavioral side effects", "Carbamazepine for focal seizures", "Vagus nerve stimulation as adjunct", "Ketogenic diet initiation"], "answer": "B", "answer_index": 1, "explanation": "In epileptic encephalopathy due to mutations like SCN8A, levetiracetam is preferred for its efficacy and lower risk of exacerbating behavioral issues in autism. Valproic acid can worsen aggression, while carbamazepine may aggravate generalized features. Dietary therapies are second-line.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 7-year-old with autism, recurrent staring spells and facial twitching, multifocal epileptiform discharges on EEG, cortical dysplasia on MRI, and a de novo mutation. The question asks for \\\"most effective first-line therapy\\\" but critically fails to specify which mutation was identified. The explanation references SCN8A, but this is not stated in the vignette. Without knowing the specific genetic mutation, multiple treatment approaches are defensible: (A) Valproic acid provides broad-spectrum coverage for multifocal epileptiform activity and is a standard first-line agent; (B) Levetiracetam is reasonable for behavioral considerations in autism; (C) Carbamazepine could address focal features suggested by cortical dysplasia. The stem's multifocal discharges and mixed semiology (staring=absence-like; twitching=focal motor) create ambiguity about seizure classification. Medical accuracy issue: The rationale's claim that valproic acid \\\"worsens aggression\\\" in autism is overstated; while behavioral effects occur, VPA remains widely used first-line for epilepsy with autism. The assertion that levetiracetam is specifically preferred for SCN8A lacks strong evidence-based consensus as a universal first-line standard. Minimal fix: Specify \\\"SCN8A mutation\\\" in the stem to justify the keyed answer's mutation-specific rationale.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 7-year-old with autism, recurrent staring spells and facial twitching, multifocal epileptiform discharges on EEG, cortical dysplasia on MRI, and a de novo mutation. The question asks for \"most effective first-line therapy\" but critically fails to specify which mutation was identified. The explanation references SCN8A, but this is not stated in the vignette. Without knowing the specific genetic mutation, multiple treatment approaches are defensible: (A) Valproic acid provides broad-spectrum coverage for multifocal epileptiform activity and is a standard first-line agent; (B) Levetiracetam is reasonable for behavioral considerations in autism; (C) Carbamazepine could address focal features suggested by cortical dysplasia. The stem's multifocal discharges and mixed semiology (staring=absence-like; twitching=focal motor) create ambiguity about seizure classification. Medical accuracy issue: The rationale's claim that valproic acid \"worsens aggression\" in autism is overstated; while behavioral effects occur, VPA remains widely used first-line for epilepsy with autism. The assertion that levetiracetam is specifically preferred for SCN8A lacks strong evidence-based consensus as a universal first-line standard. Minimal fix: Specify \"SCN8A mutation\" in the stem to justify the keyed answer's mutation-specific rationale.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-005", "question": "A 55-year-old man with Parkinson's disease develops sudden onset of dysarthria and hemiparesis. MRI shows acute infarction in the lenticulostriate territory, but vessel imaging is normal. Coagulation studies reveal an abnormality. What is the underlying mechanism?", "options": ["Cardioembolic stroke from atrial fibrillation", "Lacunar infarct due to small vessel disease", "Thrombotic stroke from antiphospholipid syndrome", "Vasculitis mimicking stroke", "Embolic stroke from levodopa-induced arrhythmia"], "answer": "C", "answer_index": 2, "explanation": "Antiphospholipid syndrome can cause thrombotic strokes in atypical territories without large vessel occlusion, especially with coagulation abnormalities. Lacunar infarcts are typically hypertensive, not matching this profile. Cardioembolism usually involves larger territories or arrhythmias, absent here.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a lenticulostriate territory infarct with normal vessel imaging and coagulation abnormality in a Parkinson's patient. Key discriminating findings: (1) lenticulostriate territory (classic lacunar location), (2) normal vessel imaging (excludes large vessel disease), (3) coagulation abnormality present, (4) no mention of hypertension, diabetes, or cardiac findings. The keyed answer C (antiphospholipid syndrome) is defensible given the coagulation abnormality and stroke in a patient without large vessel disease. However, option B (lacunar infarct from small vessel disease) is equally defensible: lenticulostriate territory is the prototypical location for lacunar strokes, normal vessel imaging is expected (small penetrating arteries aren't visualized), and coagulation abnormalities can be incidental or secondary findings. The stem states 'coagulation studies reveal an abnormality' but doesn't specify what abnormality or its clinical significance. Without specifying the type of coagulation abnormality (e.g., lupus anticoagulant, anticardiolipin antibodies) or excluding traditional lacunar risk factors explicitly, both answers remain defensible. Medical accuracy: The pathophysiology for both options is sound. Minimal fix: Specify the coagulation abnormality as 'positive lupus anticoagulant and anticardiolipin antibodies' and add 'no history of hypertension or diabetes' to exclude typical lacunar etiology.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a lenticulostriate territory infarct with normal vessel imaging and coagulation abnormality in a Parkinson's patient. Key discriminating findings: (1) lenticulostriate territory (classic lacunar location), (2) normal vessel imaging (excludes large vessel disease), (3) coagulation abnormality present, (4) no mention of hypertension, diabetes, or cardiac findings. The keyed answer C (antiphospholipid syndrome) is defensible given the coagulation abnormality and stroke in a patient without large vessel disease. However, option B (lacunar infarct from small vessel disease) is equally defensible: lenticulostriate territory is the prototypical location for lacunar strokes, normal vessel imaging is expected (small penetrating arteries aren't visualized), and coagulation abnormalities can be incidental or secondary findings. The stem states 'coagulation studies reveal an abnormality' but doesn't specify what abnormality or its clinical significance. Without specifying the type of coagulation abnormality (e.g., lupus anticoagulant, anticardiolipin antibodies) or excluding traditional lacunar risk factors explicitly, both answers remain defensible. Medical accuracy: The pathophysiology for both options is sound. Minimal fix: Specify the coagulation abnormality as 'positive lupus anticoagulant and anticardiolipin antibodies' and add 'no history of hypertension or diabetes' to exclude typical lacunar etiology.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-006", "question": "In the ICU, a 70-year-old patient with septic shock from pneumonia remains hypotensive despite vasopressors and fluids. Adrenal function testing shows a blunted cortisol response, but random cortisol is normal. What is the next step in management?", "options": ["Initiate hydrocortisone replacement therapy", "Add fludrocortisone for mineralocorticoid support", "Perform cosyntropin stimulation test", "Switch to alternative vasopressor like vasopressin", "Administer ascorbic acid and thiamine"], "answer": "D", "answer_index": 3, "explanation": "Relative adrenal insufficiency in sepsis may not respond to steroids if cortisol is normal; switching to vasopressin addresses vasoplegia more effectively. Hydrocortisone is controversial without clear deficiency. Cosyntropin is already implied by blunted response.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: The keyed answer (D) is incorrect; the best answer is A. Key stem clues: 70-year-old with septic shock, hypotensive despite vasopressors and fluids, blunted cortisol response to stimulation (implied by 'adrenal function testing'), normal random cortisol. This describes relative adrenal insufficiency (RAI) in septic shock. The blunted cortisol response indicates inadequate adrenal reserve despite normal baseline cortisol—this is the definition of RAI. Current guidelines (SSCG 2021) recommend hydrocortisone 200mg/day for patients with septic shock refractory to fluids and vasopressors. The rationale's claim that 'steroids may not respond if cortisol is normal' contradicts established practice; RAI is diagnosed by inadequate stress response, not baseline levels. Option D (vasopressin) is reasonable adjunctive therapy but doesn't address the documented adrenal insufficiency. The cosyntropin test is already completed (implied by 'blunted response'). Main logical issue: The key contradicts standard septic shock management protocols. Main medical accuracy issue: The rationale misrepresents steroid use in septic shock with documented RAI. Minimal fix: Change key to A, or clarify that patient is already on hydrocortisone and vasopressin is being added.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: The keyed answer (D) is incorrect; the best answer is A. Key stem clues: 70-year-old with septic shock, hypotensive despite vasopressors and fluids, blunted cortisol response to stimulation (implied by 'adrenal function testing'), normal random cortisol. This describes relative adrenal insufficiency (RAI) in septic shock. The blunted cortisol response indicates inadequate adrenal reserve despite normal baseline cortisol—this is the definition of RAI. Current guidelines (SSCG 2021) recommend hydrocortisone 200mg/day for patients with septic shock refractory to fluids and vasopressors. The rationale's claim that 'steroids may not respond if cortisol is normal' contradicts established practice; RAI is diagnosed by inadequate stress response, not baseline levels. Option D (vasopressin) is reasonable adjunctive therapy but doesn't address the documented adrenal insufficiency. The cosyntropin test is already completed (implied by 'blunted response'). Main logical issue: The key contradicts standard septic shock management protocols. Main medical accuracy issue: The rationale misrepresents steroid use in septic shock with documented RAI. Minimal fix: Change key to A, or clarify that patient is already on hydrocortisone and vasopressin is being added.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-007", "question": "A 38-year-old woman with chronic myeloid leukemia on dasatinib develops pleural effusions and fatigue. Cytogenetic analysis shows additional clonal evolution. What is the most appropriate therapeutic adjustment?", "options": ["Switch to imatinib to reduce pulmonary toxicity", "Add interferon-alpha for immunomodulation", "Initiate ponatinib for resistant mutations", "Dose reduce dasatinib and monitor", "Proceed to allogeneic stem cell transplant"], "answer": "C", "answer_index": 2, "explanation": "Clonal evolution in CML on dasatinib often indicates T315I mutation, for which ponatinib is effective despite pulmonary risks. Imatinib lacks potency against advanced disease. Transplant is considered but not first-line without failure of second-generation TKIs.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U (underspecified) leading to M (multiple defensible answers). Verdict: Not uniquely determinable. The stem states \\\"additional clonal evolution\\\" but critically omits which specific mutation(s) are present. Key discriminating findings: CML patient on dasatinib with pleural effusions (known dasatinib toxicity) plus clonal evolution (disease progression). The question assumes clonal evolution = T315I mutation, but clonal evolution encompasses many cytogenetic changes, most of which are NOT T315I. Without mutation analysis specifying T315I, multiple management paths are defensible: (C) ponatinib if T315I is confirmed; (E) allogeneic transplant for blast crisis or multiple resistance mutations; (D) dose reduction if effusions are limiting and disease remains chronic phase. The rationale's assertion that \\\"clonal evolution often indicates T315I\\\" is medically inaccurate—T315I represents only ~15-20% of resistance cases, and clonal evolution more commonly involves other ABL kinase domain mutations or additional chromosomal abnormalities. Main logical issue: the stem requires unstated assumption about mutation type to select between C and E. Main medical issue: conflating clonal evolution with T315I mutation. Minimal fix: Add \\\"Mutation analysis reveals T315I mutation\\\" to the stem to make ponatinib unambiguously correct.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (underspecified) leading to M (multiple defensible answers). Verdict: Not uniquely determinable. The stem states \"additional clonal evolution\" but critically omits which specific mutation(s) are present. Key discriminating findings: CML patient on dasatinib with pleural effusions (known dasatinib toxicity) plus clonal evolution (disease progression). The question assumes clonal evolution = T315I mutation, but clonal evolution encompasses many cytogenetic changes, most of which are NOT T315I. Without mutation analysis specifying T315I, multiple management paths are defensible: (C) ponatinib if T315I is confirmed; (E) allogeneic transplant for blast crisis or multiple resistance mutations; (D) dose reduction if effusions are limiting and disease remains chronic phase. The rationale's assertion that \"clonal evolution often indicates T315I\" is medically inaccurate—T315I represents only ~15-20% of resistance cases, and clonal evolution more commonly involves other ABL kinase domain mutations or additional chromosomal abnormalities. Main logical issue: the stem requires unstated assumption about mutation type to select between C and E. Main medical issue: conflating clonal evolution with T315I mutation. Minimal fix: Add \"Mutation analysis reveals T315I mutation\" to the stem to make ponatinib unambiguously correct.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-008", "question": "A 35-year-old woman in the emergency department collapses after ingesting an unknown substance. She has bradycardia, hypotension, and miosis. Atropine provides partial response, but symptoms recur. What is the definitive antidote?", "options": ["Pralidoxime for organophosphate poisoning", "N-acetylcysteine for acetaminophen", "Flumazenil for benzodiazepine overdose", "Physostigmine for anticholinergic toxicity", "Hydroxocobalamin for cyanide"], "answer": "A", "answer_index": 0, "explanation": "This cholinergic toxidrome suggests organophosphate poisoning, where pralidoxime regenerates acetylcholinesterase after initial atropine. Atropine alone is insufficient for severe cases. Other antidotes target different mechanisms not fitting the presentation.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The stem describes a classic cholinergic toxidrome (bradycardia, hypotension, miosis) with partial atropine response and symptom recurrence, strongly suggesting organophosphate poisoning. Key discriminating findings: (1) cholinergic triad (bradycardia/hypotension/miosis), (2) partial atropine response indicating muscarinic blockade is insufficient, (3) symptom recurrence suggesting ongoing acetylcholinesterase inhibition. Pralidoxime (A) is the definitive antidote because it reactivates acetylcholinesterase, addressing the underlying mechanism that atropine alone cannot reverse. Atropine only blocks muscarinic receptors but doesn't restore enzyme function. Alternative analysis: N-acetylcysteine (B) treats acetaminophen toxicity (not cholinergic); flumazenil (C) reverses benzodiazepines (causes CNS/respiratory depression, not cholinergic signs); physostigmine (D) would worsen cholinergic crisis by further inhibiting acetylcholinesterase; hydroxocobalamin (E) treats cyanide (causes metabolic acidosis/altered mental status, not cholinergic toxidrome). Medical accuracy: Fully consistent with toxicology standards. Pralidoxime is indicated for organophosphate poisoning when atropine alone is inadequate. The clinical presentation and management align with current guidelines. No logical issues; stem provides sufficient discriminating features for unique best answer. Minimal fix: None needed; item is valid and accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a classic cholinergic toxidrome (bradycardia, hypotension, miosis) with partial atropine response and symptom recurrence, strongly suggesting organophosphate poisoning. Key discriminating findings: (1) cholinergic triad (bradycardia/hypotension/miosis), (2) partial atropine response indicating muscarinic blockade is insufficient, (3) symptom recurrence suggesting ongoing acetylcholinesterase inhibition. Pralidoxime (A) is the definitive antidote because it reactivates acetylcholinesterase, addressing the underlying mechanism that atropine alone cannot reverse. Atropine only blocks muscarinic receptors but doesn't restore enzyme function. Alternative analysis: N-acetylcysteine (B) treats acetaminophen toxicity (not cholinergic); flumazenil (C) reverses benzodiazepines (causes CNS/respiratory depression, not cholinergic signs); physostigmine (D) would worsen cholinergic crisis by further inhibiting acetylcholinesterase; hydroxocobalamin (E) treats cyanide (causes metabolic acidosis/altered mental status, not cholinergic toxidrome). Medical accuracy: Fully consistent with toxicology standards. Pralidoxime is indicated for organophosphate poisoning when atropine alone is inadequate. The clinical presentation and management align with current guidelines. No logical issues; stem provides sufficient discriminating features for unique best answer. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-009", "question": "A 12-year-old girl with juvenile idiopathic arthritis on etanercept develops fever, rash, and lymphadenopathy. Serology is positive for a virus, but PCR on lymph node biopsy reveals clonal T-cell population. What is the most likely complication?", "options": ["Drug reaction with eosinophilia and systemic symptoms", "EBV-associated lymphoproliferative disorder", "Macrophage activation syndrome", "Secondary hemophagocytic lymphohistiocytosis", "TNF inhibitor-induced lymphoma"], "answer": "E", "answer_index": 4, "explanation": "TNF inhibitors like etanercept increase risk of T-cell lymphomas, especially with clonal populations on biopsy, beyond viral associations. EBV-LPD is B-cell predominant. MAS and HLH are cytokine-driven without clonality.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer is not the best answer. Key stem clues: 12-year-old on etanercept (TNF inhibitor) presents with fever, rash, lymphadenopathy; positive viral serology; lymph node biopsy shows clonal T-cell population. The critical discriminator is the clonal T-cell population on biopsy, which definitively indicates lymphoproliferative disorder. While TNF inhibitors do increase lymphoma risk, the presence of positive viral serology combined with clonal T-cell expansion in a pediatric patient on immunosuppression most strongly suggests EBV-associated T-cell lymphoproliferative disorder (option B). The rationale incorrectly states EBV-LPD is \\\"B-cell predominant\\\" – while B-cell LPD is more common, EBV-associated T-cell LPD is well-documented, especially in immunosuppressed patients. Option E (TNF inhibitor-induced lymphoma) describes the same pathologic entity but attributes causation differently; however, in the context of positive viral serology, EBV-LPD is the more specific and accurate diagnosis. The stem provides sufficient detail to discriminate, but the key selection conflates mechanism with diagnosis. Minimal fix: Either remove viral serology mention to make E clearly best, or change key to B to reflect EBV-driven pathogenesis in this immunosuppressed patient with documented clonal T-cell disease.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer is not the best answer. Key stem clues: 12-year-old on etanercept (TNF inhibitor) presents with fever, rash, lymphadenopathy; positive viral serology; lymph node biopsy shows clonal T-cell population. The critical discriminator is the clonal T-cell population on biopsy, which definitively indicates lymphoproliferative disorder. While TNF inhibitors do increase lymphoma risk, the presence of positive viral serology combined with clonal T-cell expansion in a pediatric patient on immunosuppression most strongly suggests EBV-associated T-cell lymphoproliferative disorder (option B). The rationale incorrectly states EBV-LPD is \"B-cell predominant\" – while B-cell LPD is more common, EBV-associated T-cell LPD is well-documented, especially in immunosuppressed patients. Option E (TNF inhibitor-induced lymphoma) describes the same pathologic entity but attributes causation differently; however, in the context of positive viral serology, EBV-LPD is the more specific and accurate diagnosis. The stem provides sufficient detail to discriminate, but the key selection conflates mechanism with diagnosis. Minimal fix: Either remove viral serology mention to make E clearly best, or change key to B to reflect EBV-driven pathogenesis in this immunosuppressed patient with documented clonal T-cell disease.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-010", "question": "A 68-year-old man with amyotrophic lateral sclerosis presents with progressive dysphagia and aspiration. Videofluoroscopy shows pharyngeal weakness. Non-invasive ventilation is in use. What is the most appropriate intervention?", "options": ["Percutaneous endoscopic gastrostomy placement", "Botulinum toxin injection into cricopharyngeus", "Tracheostomy for airway protection", "Speech therapy with swallowing exercises", "Pharmacologic enhancement with edrophonium"], "answer": "B", "answer_index": 1, "explanation": "In ALS with cricopharyngeal dysfunction causing dysphagia, botulinum toxin relaxes the muscle to improve swallowing, a targeted approach before invasive feeding. PEG is for nutrition but not dysphagia mechanism. Tracheostomy addresses ventilation, not swallowing.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - PEG (A) is the correct best answer, not botulinum toxin (B). The stem describes a 68-year-old ALS patient with progressive dysphagia and aspiration, with videofluoroscopy showing pharyngeal weakness (not specifically cricopharyngeal dysfunction). Key discriminating findings: progressive dysphagia with aspiration in ALS, pharyngeal weakness on imaging, already on NIV. The clinical problem is managing unsafe swallowing with aspiration risk in advanced ALS. PEG placement (A) is standard care for ALS patients with dysphagia and aspiration to provide safe nutrition and prevent aspiration pneumonia. The keyed answer (B) assumes cricopharyngeal dysfunction, but the vignette only mentions \\\"pharyngeal weakness\\\" - a broader finding. Botulinum toxin for cricopharyngeus is a niche intervention for isolated cricopharyngeal bar/achalasia, not standard for generalized pharyngeal weakness in ALS. The rationale incorrectly states botulinum toxin is used \\\"before invasive feeding\\\" - this contradicts standard ALS management guidelines where PEG is recommended early for dysphagia with aspiration. Main logical issue: The stem does not specify cricopharyngeal dysfunction; it describes pharyngeal weakness, making B unsupported. Main medical accuracy issue: Botulinum toxin is not standard first-line for ALS dysphagia with aspiration; PEG is. Minimal fix: Change stem to explicitly state \\\"cricopharyngeal bar on videofluoroscopy\\\" or change key to A.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - PEG (A) is the correct best answer, not botulinum toxin (B). The stem describes a 68-year-old ALS patient with progressive dysphagia and aspiration, with videofluoroscopy showing pharyngeal weakness (not specifically cricopharyngeal dysfunction). Key discriminating findings: progressive dysphagia with aspiration in ALS, pharyngeal weakness on imaging, already on NIV. The clinical problem is managing unsafe swallowing with aspiration risk in advanced ALS. PEG placement (A) is standard care for ALS patients with dysphagia and aspiration to provide safe nutrition and prevent aspiration pneumonia. The keyed answer (B) assumes cricopharyngeal dysfunction, but the vignette only mentions \"pharyngeal weakness\" - a broader finding. Botulinum toxin for cricopharyngeus is a niche intervention for isolated cricopharyngeal bar/achalasia, not standard for generalized pharyngeal weakness in ALS. The rationale incorrectly states botulinum toxin is used \"before invasive feeding\" - this contradicts standard ALS management guidelines where PEG is recommended early for dysphagia with aspiration. Main logical issue: The stem does not specify cricopharyngeal dysfunction; it describes pharyngeal weakness, making B unsupported. Main medical accuracy issue: Botulinum toxin is not standard first-line for ALS dysphagia with aspiration; PEG is. Minimal fix: Change stem to explicitly state \"cricopharyngeal bar on videofluoroscopy\" or change key to A.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}]